Quality Management of Steroid Hormone Assays
This chapter describes the principles and practices of quality management of the steroid hormone in clinical laboratory service, and the assessment of the quality of that service by the author’s EQA programme (UK NEQAS for Steroid Hormones).
KeywordsProficiency Test Continuous Quality Improvement External Quality Assessment Internal Quality Control External Quality Assessment Scheme
The UK NEQAS for Steroid Hormones is funded by subscriptions from participants throughout the UK and overseas. Administrative support is provided by the staff of the Wolfson EQA Laboratory, part of the University Hospital Birmingham NHS Foundation Trust, directed by Dr. David Bullock. Scientific guidance is provided by the UK NEQAS Special Advisory Group for Immunoassay (Chair Dr. Geoff Beckett). Policy support is given by the UK NEQAS Consortium Executive (chair Mrs Barbara De La Salle). UK NEQAS could not function without the support of the National Blood Service at Birmingham, and the work of the Wolfson Computer Laboratory, University Hospital Birmingham NHS Foundation Trust, directed by Dr. Ian Clarke, in developing and maintaining the EQAS Computer System, which is warmly acknowledged.
It should be noted that Siemens Healthcare Medical Solutions have now absorbed Bayer Diagnostics and the Diagnostic Products Corporation. Therefore all references to method names such as Bayer Centaur and DPC Immulite should be understood now to mean Siemens Centaur and Siemens Immulite.
- Barnard G, Kohen F (1990) Idiometric assay: noncompetitive immunoassay for small molecules typified by the measurement of oestradiol in serum. Clin. Chem. 36; 1945–1950.Google Scholar
- Ekins R (1983) The precision profile: its use in assay design, assessment and quality control. In Immunoassays for Clinical Chemistry (eds Hunter WM, Corrie JET). Churchill-Livingstone, Edinburgh. pp. 76–105.Google Scholar
- Ekins R (1991b) Immunoassay design and optimisation. In Principles and Practice of Immunoassay (eds Price C, Newman D), Chapter 5. Macmillan, London. pp. 96–153.Google Scholar
- EU Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices (1998-12-07 OJ No L 331/1).Google Scholar
- Fraser CG, Hyltoft-Petersen P (1993a) Desirable standards for laboratory tests if they are to fulfil medical needs. Clin. Chem. 39; 1447–1455.Google Scholar
- Fuentes-Aderiu X (2000) Trueness and Uncertainty website guest essay at www.westgard.com/guest15.htm
- Healy MJR (1979) Outliers in clinical chemistry quality control schemes. Clin. Chem. 25; 675–677.Google Scholar
- Jeffcoate SL (1981) Efficiency and Effectiveness in the Clinical Laboratory. Academic, London.Google Scholar
- Libeer J-CPM (1993) External Quality Assessment in Clinical Laboratories – European perspectives: today and tomorrow. Ph.D. thesis, University of Antwerp, Belgium.Google Scholar
- Panteghini M (2007) Traceability, reference systems and result comparability. Clin. Biochem. Rev. 28; 97–104.Google Scholar
- Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P (2003) Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin. Chem. 49; 1381–1395.CrossRefGoogle Scholar
- Westgard JO, Petersen JH, Groth T (1984) The quality costs of an analytical process: development of quality costs models based on predicitive value theory. Scand. J. Clin. Lab. Invest. 44(Suppl 172); 221–236.Google Scholar